News

New Episode of Never a Dull Moment – The CFO

🎙️ Never a Dull Moment podcast has released a new episode! 🎙️ In this conversation, host Ziad Henry Moukheiber chats with guest Michael Bayer, CFO of one of Boston Harbor Angels portfolio companies Wasabi Technologies. This fascinating discussion is kicked off with Michael's description of a CFO as a storyteller. Tune in to hear more about about how the role of CFO has evolved!
Read more...

The Active Archive Alliance Welcomes Wasabi Technologies to the Organization

The Active Archive Alliance today announced that Wasabi Technologies, the hot cloud storage company, has joined the organization. The Active Archive Alliance is a collaboration of industry-leading storage systems and software vendors that collectively support and promote the use of active archives in providing modern solutions for today's data growth challenges. "Wasabi plays an important role in providing fully integrated solutions with AI enhancements, security and affordability built in – furthering the use of active archives for intelligent data management."...
Read more...

Akston Named Best Start-Up for 2024 in the S&P Global Animal Health Awards

Akston, the biotech built for pets, has been awarded the Best Start-Up of 2024 by S&P Global Animal Health at the Animal Health, Nutrition, and Technology Innovation Europe 2025 conference in London. The award was presented by Joseph Harvey, Editor, S&P Global Animal Health, and accepted by Akston CEO, Todd Zion. Read more >>
Read more...

Light Within the Black Hole of Concussion Therapeutics

Last September, the Fédération Internationale de Football Association (FIFA) and the World Health Organization launched the “Suspect and Protect” concussion awareness campaign. In the past few years, the U.S. Department of Defense, the National Hockey League, and the National Football League each introduced plans to minimize concussions, including updating their concussion protocols. And large pharmaceutical companies have done…little. For companies active in this space, their slow progress may be more related to investors’ misperceptions of the topic than the science itself....
Read more...

Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate

On Friday, Corbus Pharmaceuticals Holdings, Inc. announced that data from its US and UK first-in-human dose escalation clinical study of CRB-701 (SYS6002) were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium. The Phase 1 Western dose escalation study enrolled participants with metastatic urothelial cancer (mUC) and other solid tumors associated with Nectin-4 expression. These included several tumor types not previously explored in China. Read more >>
Read more...

Aras to Celebrate 25 Years of Innovation at ACE 2025 in Boston

...2025 marks a major milestone as Aras celebrates 25 years of continuous innovation while looking ahead to AI-driven PLM, advanced digital thread strategies, and scalable transformation initiatives. ACE 2025 will explore how today’s industry pioneers are establishing seamless digital threads across the entire lifecycle to enhance resilience, efficiency, and long-term competitiveness. Read more >>
Read more...

RevBio Issued a Key Patent for its Regenerative Bone Adhesive Technology by the United States Patent and Trademark Office

The United States Patent and Trademark Office recently issued patent 12,178,937 entitled “Compositions and Methods for Adhesion to Surfaces,” which constitutes the 10th U.S. patent that covers the TETRANITE bone adhesive technology. This patent expands the protected technology to include injectable mineral-organic structural bone adhesive compositions that comprise alpha tricalcium phosphate. The issuance of this patent complements RevBio’s existing U.S. patent 11,638,777, which covers the method of repairing fractured bone using the aforementioned adhesive composition. These recently issued patents enlarge...
Read more...